Tenax Therapeutics logo

Tenax TherapeuticsNASDAQ: TENX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

04 April 1994

Next earnings report:

14 May 2025

Last dividends:

N/A

Next dividends:

N/A
$16.49 M
-50%vs. 3y high
22%vs. sector
-vs. 3y high
-vs. sector
-98%vs. 3y high
19%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 20 Nov 2024 21:22:56 GMT
$4.84-$0.02(-0.44%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

TENX Latest News

Tenax Therapeutics, Inc. (TENX) Guggenheim Healthcare Innovation Conference (Transcript)
seekingalpha.com15 November 2024 Sentiment: NEUTRAL

Tenax Therapeutics, Inc. (NASDAQ:TENX ) Guggenheim Healthcare Innovation Conference November 13, 2024 1:00 PM ET Company Participants Chris Giordano - President and CEO Stuart Rich - Chief Medical Officer Conference Call Participants Seamus Fernandez - Guggenheim Securities Seamus Fernandez Good afternoon, everybody. And welcome again to Guggenheim Securities Inaugural Healthcare Innovation Conference.

Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
globenewswire.com31 October 2024 Sentiment: POSITIVE

CHAPEL HILL, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it will participate in the Guggenheim Healthcare Innovation Conference in Boston, Massachusetts, from November 11-13, 2024. Tenax's CEO, Chris Giordano, will provide an update on the company and the ongoing development of levosimendan, in a session investors can attend live or via webcast.

Why Is Tenax Therapeutics (TENX) Stock Up 29% Today?
investorplace.com06 August 2024 Sentiment: POSITIVE

Tenax Therapeutics (NASDAQ: TENX ) stock is soaring higher on Tuesday after the company announced the completion of an oversubscribed private placement for its shares. This oversubscribed private placement has Tenax Therapeutics expecting $100 million in gross proceeds.

Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement
globenewswire.com06 August 2024 Sentiment: POSITIVE

CHAPEL HILL, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (the “Company” or “Tenax Therapeutics”), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it has entered into a securities purchase agreement for an oversubscribed private placement financing that is expected to result in total gross proceeds of approximately $100 million to the Company, before deducting placement agent fees and other private placement expenses.

Why Is Tenax Therapeutics (TENX) Stock Down 64% Today?
InvestorPlace08 February 2024 Sentiment: NEGATIVE

Tenax Therapeutics (NASDAQ: TENX ) stock is falling hard on Thursday after the pharmaceutical company announced details for a public offering of its shares. That public offering has Tenax Therapeutics selling 1.6 million units.

Why Is Tenax Therapeutics (TENX) Stock Up 300% Today?
InvestorPlace13 November 2023 Sentiment: POSITIVE

Shares of pharmaceutical specialist Tenax Therapeutics (NASDAD: TENX ) are skyrocketing on Monday amid encouraging regulatory news. More specifically, with a focus on addressing cardiovascular and pulmonary diseases with high unmet medical need, Tenax has received clearance for its investigational new drug (IND) application for its pulmonary hypertension therapeutic.

Tenax Therapeutics shares soar after FDA clears IND for hypertension candidate NX-103
Proactive Investors13 November 2023 Sentiment: POSITIVE

Shares of Tenax Therapeutics surged over 300% after it announced the US Food and Drug Administration has reviewed and cleared its Investigational New Drug (IND) application for its hypertension candidate, TNX-103. The specialty pharmaceutical company said the  FDA's enables it to proceed with the first of two Phase 3 studies for TNX-103 (oral Levosimendan) for the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF).

What type of business is Tenax Therapeutics?

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

What sector is Tenax Therapeutics in?

Tenax Therapeutics is in the Healthcare sector

What industry is Tenax Therapeutics in?

Tenax Therapeutics is in the Biotechnology industry

What country is Tenax Therapeutics from?

Tenax Therapeutics is headquartered in United States

When did Tenax Therapeutics go public?

Tenax Therapeutics initial public offering (IPO) was on 04 April 1994

What is Tenax Therapeutics website?

https://www.tenaxthera.com

Is Tenax Therapeutics in the S&P 500?

No, Tenax Therapeutics is not included in the S&P 500 index

Is Tenax Therapeutics in the NASDAQ 100?

No, Tenax Therapeutics is not included in the NASDAQ 100 index

Is Tenax Therapeutics in the Dow Jones?

No, Tenax Therapeutics is not included in the Dow Jones index

When was Tenax Therapeutics the previous earnings report?

No data

When does Tenax Therapeutics earnings report?

The next expected earnings date for Tenax Therapeutics is 14 May 2025